External Networks in the Drug Industry
As they seek to create external networks to gain access to innovation, drug companies follow one of three models: the discovery stimulator, the idea acquirer, or the product acquirer. A variety of forces--from earning pressure to competition for research talent to the need to launch products globally--are all contributing to the complexity of managing in this new environment.
You may also be interested in...
High-profile experts including Anthony Fauci and Adrian Hill share views at the ICMR symposium on progressing safe COVID-19 vaccines backed by ethical trials executed with appropriate scientific rigor. Human challenge studies, "vaccine nationalism" and equitable access were among the key issues deliberated, while India committed to making its coronavirus vaccines and related capabilities available to the world.
The company has executed $400m worth of deals with smaller governments reflecting a $32-$37 price per dose for the two-shot mRNA-1273 vaccine, but said larger deals will be done at lower prices.
A diclofenac topical analgesic is first, likely followed by a line extension for its Prevacid 24HR PPI brand. Perrigo also plans to introduce natural-based products that “leverage our expertise in Europe."